Acquisition by Kathiresan Sekar of 30000 shares of Verve Therapeutics subject to Rule 16b-3
| VERV Stock | USD 11.21 0.04 0.36% |
Slightly above 55% of Verve Therapeutics' sophisticated investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Verve Therapeutics suggests that some traders are interested. Verve Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Verve Therapeutics' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Verve Therapeutics Director, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Verve Therapeutics Fundamental Analysis
We analyze Verve Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verve Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verve Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Verve Therapeutics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Verve Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Verve Therapeutics stock to make a market-neutral strategy. Peer analysis of Verve Therapeutics could also be used in its relative valuation, which is a method of valuing Verve Therapeutics by comparing valuation metrics with similar companies.
Peers
Verve Therapeutics Related Equities
| PRME | Prime Medicine, | 13.89 | ||||
| IPSC | Century Therapeutics | 3.51 | ||||
| CRSP | Crispr Therapeutics | 1.88 | ||||
| ADPT | Adaptive Biotechnologies | 0.85 | ||||
| CRBU | Caribou Biosciences | 0.71 | ||||
| NTLA | Intellia Therapeutics | 0.10 | ||||
| BPMC | Blueprint Medicines | 0.11 | ||||
| RLAY | Relay Therapeutics | 1.51 | ||||
| BEAM | Beam Therapeutics | 2.27 | ||||
| SANA | Sana Biotechnology | 2.36 | ||||
| EDIT | Editas Medicine | 2.67 |
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.